Development, production and marketing of innovative medicines, especially in oncology.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Lianyungang · Shanghai · GuangzhouNew on Amplifa
About Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals Co., Ltd. was founded in 1970 and is a publicly listed pharmaceutical company (600276.SH / 01276.HK) with more than 20,000 employees. The company researches, produces and markets high-quality medicines; to date, 27 Class 1 new medicines (innovative medicines) and 6 Class 2 new medicines have been approved. The focus areas are oncology, metabolic and cardiovascular diseases, immunology and respiratory diseases, and neuroscience. At the Guangzhou site, antibody protein drugs and antibody-drug conjugates are produced in accordance with GMP; a project for the research and industrialization of mRNA medicines is documented. At the Lianyungang site (Dapu industrial zone), active pharmaceutical ingredients are manufactured on six production lines, including polypeptide synthesis with reactors and multipeptide synthesis systems. Since the IPO in 2000, revenue has grown from under 0.5 billion to 27.7 billion CNY (as of 2021); the company supplies worldwide.
- Site
- 0 Lianyungang, Jiangsu
- Processes
- Production of antibody protein drugs and antibody-drug conjugates (GMP), R&D and industrialization of innovative mRNA medicines, API production (6 production lines, including peptide synthesis), Active ingredient and drug research, Production, Marketing of medicines, Development of innovative medicines (Class 1: 27, Class 2: 6)
- Founded
- 1970
- Employees
- 20000+
- Industries
- Pharmaceutical industry, Oncology, Metabolic and cardiovascular diseases, Immunology and respiratory diseases, Neuroscience
- 01
Active ingredient and drug research
- 02
Production of active ingredients and medicines
- 03
Marketing of medicines
Locations
Lianyungang
CNHeadquarters and API production
- Reactors
- Multipeptide synthesis systems
Shanghai
CNSite / Investor Relations
Guangzhou
CNProduction and R&D site (biopharmaceuticals)
- Cartridge filling lines
- PFS filling lines
- Bioreactors
- Ultrafiltration systems
- Inline dilution systems
Industries
Processes & technical limits
| Processes | Tolerance | Max. part | Weight | Lot size | Materials |
|---|---|---|---|---|---|
| Production of antibody protein drugs and antibody-drug conjugates (GMP)Assembly | – | – | – | – | – |
| R&D and industrialization of innovative mRNA medicinesEngineering | – | – | – | – | – |
| API production (6 production lines, including peptide synthesis)Engineering | – | – | – | – | – |
7 Anlagen & Maschinen
| Machine | Manufacturer / model | Quantity | Working area | Year built | Site |
|---|---|---|---|---|---|
| Cartridge filling lines | – | – | – | – | 广州市黄埔区康耀南路55号 |
| PFS filling lines | – | – | – | – | 广州市黄埔区康耀南路55号 |
| Bioreactors | – | – | – | – | 广州市黄埔区康耀南路55号 |
| Ultrafiltration systems | – | – | – | – | 广州市黄埔区康耀南路55号 |
| Inline dilution systems | – | – | – | – | 广州市黄埔区康耀南路55号 |
| Reactors | – | – | – | – | 连云港经济技术开发区大浦工业区金桥路22号 |
| Peptide synthesis systems | – | – | – | – | 连云港经济技术开发区大浦工业区金桥路22号 |
Additional services
Company History
- 1970
Founded as a small pharmaceutical factory in northern Jiangsu (Su Bei); a Party cell was established in the same year.
- 1997
Renamed to the current name; founding of the Party committee
- 2000
IPO; revenue has since risen from under 0.5 billion to 27.7 billion CNY (as of 2021)
- 2020
50th company anniversary